Several of these studies propose specific reliable biomarkers of AD in CSF [4] and several reviews have gathered information from them to demonstrate the consistent role for amyloid-β (Aβ1-42), total tau (T-tau), and phosphorylated tau (P-tau) [5,6], as well as other proteins such as VGF nerve growth factor inducible (decreased in AD) or CH3L1 (increased in AD) [7,8], and certain family of proteins, such as granins or pentraxins, as reliable hallmarks of AD relevant for diagnosis [6,9,10]. The gene discussed is MAPT; the disease is Alzheimer disease.